Community Health Network, Inc

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Colorectal cancer4 trials
• Head and neck cancer3 trials
• Melanoma3 trials
• Pancreatic cancer3 trials
• Bladder cancer2 trials
• Cervical cancer2 trials
• Endometrial cancer2 trials
• Gastric and oesophageal cancer2 trials
• Atrial fibrillation1 trial
• Chronic lymphocytic leukaemia1 trial
• Kidney cancer1 trial
• and 5 more

Phase

• Phase 34 trials
• Phase 13 trials
• Phase 1/22 trials
• Phase 21 trial

Status

• Recruiting7 trials
• Terminated3 trials
• Active, not recruiting1 trial

Lead sponsor

• Pfizer4 trials
• Incyte Corporation2 trials
• Seagen, a wholly owned subsidiary of Pfizer2 trials
• GV20 Therapeutics1 trial
• Hamilton Health Sciences Corporation1 trial
• and 1 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

  Contact: Relay Therapeutics, Inc

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

  Contact: Krishna Malineni, MD (principal investigator)

• Recruiting

  A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

  NCT05669430· Phase 1/2· GV20 Therapeutics· Source

  Contact: GV20 Therapeutics

• Recruiting

  A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  NCT04389632· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

  NCT03485209· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Colorectal cancer2 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Terminated

  A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

  NCT06974734· Phase 1· Pfizer· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Incyte Corporation· Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Phase 1· Pfizer· Source